 
  
 
ASSIST ™ Registry Protocol  
Rev. AB, 29 March 2019 
[STUDY_ID_REMOVED]  
 
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.     
 Page [ADDRESS_908601]  
Fremont, [LOCATION_004] [ZIP_CODE] -6515  
Email: Alice.L [EMAIL_12809]  
Coordinating 
Investigators:  Rishi Gupta, MD  
Director of The Stroke Program at the WellStar Health System  
WellStar Medical Group  
Neurosurgery  
[ADDRESS_908602]  
Marietta, G A [ZIP_CODE]   
[LOCATION_003]  
Email: [EMAIL_12810]  
Markus A. Möhlenbruch , MD  
Senior Physician Section Manager for Interventional Neuroradiology  
University Hospi[INVESTIGATOR_672208] 400  
[ZIP_CODE] Heidelberg  
[LOCATION_013]  
Email:  [EMAIL_12811] -heidelberg.de  
Study Centers  A current list of sites will be maintained in the Sponsor’s study files 
Date of Issue  19 April 2018 , Rev AA  
Date(s) of Amendment(s)  29 March  2019, Rev AB  
This protocol  contains confidential information  for use by [CONTACT_672244] . It should be held confidential and maintained in a secure 
location. Do not copy or distribute without written permission  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page [ADDRESS_908603]™ Registry Protocol  Signature [CONTACT_354916] : ASSIST™ Registry  
Study Center :  
 (Print name [CONTACT_205425])  
 
We, the undersigned,  have read and understand the protocol  specified above and agree on its content. We 
agree to perform and conduct the study as described in the protocol . In addition, when applicable, we agree 
to enlist sub -investigators who also agree to perform and conduct the study as described in the protoc ol. 
 
         
Principal Investigator [INVESTIGATOR_672209] / MMM / YYYY  
 
 
            
Co-Investigator Signature   □ N/A 
 
              
Printed Name          [INVESTIGATOR_1652] / MMM / YYYY  
 
  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 3 of 41 
 
  
Clinical Protocol  Synopsis  
Primary Objective  The purpose of this Registry  is to assess the procedural success and clinical 
outcomes associated with various operator  techniques  for mechanical 
thrombectomy in large vessel occlusions  (LVO)  in the anterior circulation . 
This Registry  will also collect  data, including time -to-treatment and quality of 
life measures, to allow for subset analyses that may be used for regulatory 
submissions and/or reimbursement dossiers . 
Primary Clinical 
Outcome  1. Severity of disability at Day 90  (± 14) assessed by  [CONTACT_672245] 
(mRS)  with a good function al outcome defined as  mRS of 0 -2 for each 
technique  
Secondary Clinical 
Outcomes  1. Excellent f unctional outcome defined as  mRS of 0 -1 at Day 90  (± 14)  
2. An “early response” at Discharge /Day5 -7 (whichever is earlier) defined as 
a NIHSS drop of  ≥10 points from baseline or NIHSS score of 0 or 1  
3. Quality of Life at Day 90  (± 14) assessed by [CONTACT_399128] (EQ5D 5L) 
Primary Procedural 
Outcome  1. eTICI [ADDRESS_908604] pass  as adjudicated by [CONTACT_672246]:  
1. eTICI 2b50, eTICI 2b67, eTICI 2c , and/or eTICI [ADDRESS_908605] pass , after 
primary technique used, and at the end of the endovascular procedure  
2. Time from groin puncture to eTICI 2b50,  eTICI 2b67, eTICI 2c, and/or  
eTICI [ADDRESS_908606] pass  
3. Overall time from groin puncture to achieve eTICI 2c or 3  and final 
reperfusion  
Safety  
Outcomes  1. All-cause mortality and stroke -related mortality up to 90 Days  (±14)  
2. Device and /or procedure related SAEs up to 90 Days  (±14)  
3. Neurological deterioration at 24 ( -6/+24) hours post procedure defined as a 
NIHSS  increase ≥4 points from baseline  
4. Symptomatic  intracranial hemorrhage ( SICH) adapted from European 
Cooperative Acute Stroke Study (ECASSIII) as any apparent extravascu lar 
blood in the brain or within the cranium that is associated with clinical 
deterioration defined by a NIHSS increase of four points or more from 
baseline up to 24 ( -6/+24) hours  
5. Embolization to New Territory  adjudicated by [CONTACT_672247] -procedure non -invasive 
imaging and cerebral angiography to include but not limited to:  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 4 of 41 
 
 • The Alberta Stroke Program Early CT S core (ASPECTS)  
• Collateral  Flow G rade 
• eTICI Score for Each Pass 
• Occlusion Location  
• Pre-procedure Perfusion Assessment  
• Post-procedure Hemorrhagic Transformation  
• Embolization to New Territory (ENT)  
• Vessel Size  
Registry Device s Data will be collected on the use of Stryker market -released neurovascular 
mechanical access and mechanical thrombectomy devices  that are currently 
available or that may be launched during the conduct of the Registry , including 
but not limited to:  
• AXS Infinity LS™ Long Sheath  (LS)  
• AXS Infinity LS™ Plus Long Sheath  
• FlowGate2™ Balloon Guide Catheter  (BGC)  
• Merci® Balloon Guide Catheter  
• AXS Catalyst® 5 Distal Access Catheter  (DAC)  
• AXS Catalyst® 6 Distal Access Catheter  
• AXS Catalyst® 7 Distal Access Catheter  
• Trevo® Retriever  
• AXS Vecta ™ 71 Aspi[INVESTIGATOR_672210]  (Asp Cath)  
• AXS Vecta ™ 74 Aspi[INVESTIGATOR_672211]  
• Medela Dominant Flex  Pump   
Device Sizes  All product sizes approved for use by [CONTACT_672248] a prospective, global,  consecutive enrollment Re gistry of anterior 
circulation acute ischemic stroke patients  with a LVO  who undergo treatment 
with one of the interventional techniques using  Stryker Neurovascular  (SNV)  
devices  for the first pass . 
Planned Number of 
Subjects  Up to 1500 subjects  
Planned Number of 
Sites  Up to 100 sites worldwide  
Study Duration  Up to 48 months  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 5 of 41 
 
 Follow -Up Schedule  • 24 (-6/+24)  hours post -index stroke procedure  
• Discharge / Day 5 -7 (whichever is earlier)  
• Day 30 (± 14)  
• Day 90  (± 14)  
Inclusion  
Criteria  1. Subjects  who experienced  acute ischemic stroke (AIS) ,  eligible for  
restoration of blood flow using Stryker Neurovascular market -released 
products in the neurovasculature to remove thrombus  
2. Occlusion of intracranial anterior circulation vessel  
3. Subject or subject’s legally authorized representative (LAR) has s igned the 
informed consent form prior to or within [ADDRESS_908607]  thrombectom y pass in the neurovasculature per 
Instructions For Use (IFU1): 
Technique Category  Devices*  
SR Classic  SR + BGC  
SR Combination  SR + Asp Cath ± Pump + BGC or LS  
Direct Aspi[INVESTIGATOR_672212] ± Pump + BGC or LS  
*Defined d evices must be SNV market -released  products.  
 
Exclusion Criteria  The subject is participating in another device trial or any other  clinical trial 
where the study procedure or treatment mig ht confound th is study ’s endpoint.  
Statistical Methods  
Statistical Test 
Method  Sample size is estimated based on the desired  measurement  precision of primary 
clinical and procedural outcomes. General summary and descriptive statistics 
will be used to analyze the study data. Logistic regression will be used to 
evaluate predictors of good outcomes in  each of the techniques . Further details 
are provided in the S tatistical Analysis Plan (SAP) . 
 
 
 
 
 
  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page [ADDRESS_908608] Registry Data  ................................ ................................ ...............  11 
2 Existing Clinical Data  ................................ ................................ ................................ ..................  11 
2.1 TREVO Stud y ................................ ................................ ................................ ...................  11 
2.2 TREVO 2 Study  ................................ ................................ ................................ ................  12 
2.3 MR CLEAN Study  ................................ ................................ ................................ ............  12 
2.4 TREVO Registry  ................................ ................................ ................................ ...............  13 
2.5 DWI or CTP with Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes 
Undergoing Neurointervention (DAWN™) Trial  ................................ ............................  13 
3 Descriptions of Registry Devices  ................................ ................................ ................................ . 14 
3.1 Registry Devices  ................................ ................................ ................................ ...............  14 
3.2 Device Labeling  ................................ ................................ ................................ ................  14 
4 Registry Objective  ................................ ................................ ................................ ........................  15 
4.1 Primary Clinical Outcome  ................................ ................................ ................................  15 
4.2 Secondary Clinical Outcomes  ................................ ................................ ...........................  15 
4.3 Primary Procedural Outcomes  ................................ ................................ ..........................  15 
4.4 Secondary Procedural Outcomes  ................................ ................................ ......................  15 
4.5 Safety Outcomes  ................................ ................................ ................................ ...............  15 
4.6 Time Points Assessments  ................................ ................................ ................................ .. 16 
4.7 Core Lab Assessments  ................................ ................................ ................................ ...... 16 
5 Registry Design  ................................ ................................ ................................ ............................  16 
5.1 Sites  ................................ ................................ ................................ ................................ ... 16 
5.2 Duration  ................................ ................................ ................................ ............................  16 
5.3 Justification for the Registry Design  ................................ ................................ .................  17 
5.4 Method of Enrollment  ................................ ................................ ................................ ....... 17 
6 Study Population  ................................ ................................ ................................ ..........................  17 
6.1 Selection Criteria  ................................ ................................ ................................ ..............  17 
6.1.1  .... Inclusion Criteria  ................................ ................................ ................................ . 17 
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 7 of 41 
 
 6.1.2  .... Exclusion Criteria  ................................ ................................ ................................  18 
6.2 Withdrawal and Replacement of Subjects  ................................ ................................ ........  18 
6.3 Enrollment Controls  ................................ ................................ ................................ ..........  18 
7 Study Proced ures ................................ ................................ ................................ .........................  18 
7.1 Written Informed Consent  ................................ ................................ ................................  18 
7.2 Pre-Procedure Assessments  ................................ ................................ ..............................  18 
7.3 Procedure/Treatment  ................................ ................................ ................................ .........  19 
7.3.1  .... Angiogram Procedure  ................................ ................................ ..........................  19 
7.3.2  .... Thrombectomy Procedure  ................................ ................................ ....................  19 
7.4 24 hours  (-6/+24) Post Procedure  ................................ ................................ .....................  21 
7.5 Discharge/Day 5 -7 (whichever is earlier)  ................................ ................................ .........  [ADDRESS_908609] Discharge Follow Up  ................................ ................................ ..................  21 
7.6 Day 30 (±14 days)  ................................ ................................ ................................ .............  22 
7.7 Day 90 (±14 days)  ................................ ................................ ................................ .............  [ADDRESS_908610] Nonconformities  ................................ .........  28 
12.5  Reporting to Regulatory Authorities / IRBs / ECs Investigators  ................................ ...... 29 
13 Risk Benefit Analysis  ................................ ................................ ................................ ...................  29 
13.1  Risk Minimization  ................................ ................................ ................................ ............  29 
14 Steering Committee  ................................ ................................ ................................ .....................  29 
15 Ethical Consi derations ................................ ................................ ................................ .................  30 
15.1  Compliance with Good Clinical Practices (GCP)  ................................ .............................  30 
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page [ADDRESS_908611] / Ethics Committee  ................................ ...............................  [ADDRESS_908612] Retention  ................................ ................................ ................................ ..............  30 
16.3  Criteria fo r Suspending/Terminating a Study Center  ................................ .......................  31 
17 References  ................................ ................................ ................................ ................................ ..... 32 
18 Appendices  ................................ ................................ ................................ ................................ .... 35 
Appendix A.  Abbreviation s ................................ ................................ ................................ ....... 35 
Appendix B.  Definitions  ................................ ................................ ................................ ...........  37 
Appendix C.  Expanded TICI (eTICI) Perfusion Categories  ................................ .....................  40 
Appendix D.  Informed Consent Form Template  ................................ ................................ ....... 41 
    
 
 
 
 
 
 
 
 
 
 
 
  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page [ADDRESS_908613] few years, treatment for stroke has rapi[INVESTIGATOR_672213]  (tPA) and endovascular therap y 
for select patients, based on positive outcomes shown in the five pi[INVESTIGATOR_672214] [ADDRESS_908614] demonstrated that the 
faster the time to recanalization or reperfusion, the better the functional outcom e for the patient.7,8,9,10,11 Two 
factors play key roles in determining time to reperfusion: 1) efficiency and effectiveness of mechanical 
thrombectomy techniques, and 2) triage, transport and treatment times.  
1.1 Mechanical Thrombectomy Techniques  
In the contex t of AIS, endovascular therapy is often considered a single treatment modality; however, it can 
include a number of different, but related strategies —some of which may be more effective than others.12,13,14 
Common endovascular strategies can include chemical clot dissolution with local delivery of tPA or 
recanalization of arterial occlusion by [CONTACT_672249], aspi[INVESTIGATOR_1516], or retrieval using one or more mechanical 
devices. Furthermore, the type of mechanical device used and/or the combination of mechanical devi ces used 
for endovascular therapy might have a significant influence on reperfusion time and, as a result, functional 
outcome.15,16,[ADDRESS_908615] data on  the following devices  ( including but not limited to): the 
AXS Infinity LS Long Sheath,  the AXS Infinity LS Plus Long Sheath,  the FlowGate2 and Merci Balloon 
Guide Catheters (BGC),  the AXS Catalyst Distal Access Catheters (DAC), the AXS Vecta Aspi[INVESTIGATOR_672215],  the Trevo Retriever , and the Dominant Flex Medela pump . 
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 10 of 41 
 
 Data from subjects treated with the following mechanical thrombectomy techniques will be evaluated . These 
devices w ill be evaluated in the context of pre -defined mechanical thrombectomy techniques .  
These techniques were chosen to be evaluated  based on physician input, current worldwide clinical practice, 
as well as recent scientific studies of adjunctive therapi[INVESTIGATOR_672216]. For example, the use of a stent 
retriever in combination with a BGC (‘ SR Classic’) for the treatment of AIS in the anterior circulation has 
been shown to improve angiographic results and procedure duration time compared to the use of a sten t 
retriever alone. [ADDRESS_908616] 
adherence to stroke performance metrics like door to needle time, imaging -to-puncture, imaging -to-perfusion 
time and comprehensive metrics like symptom onset to reperfusion time can vastly improve the chances of 
good clinical outcome.25,25,26,27       
For example, in the STRATIS Registry using only Solitaire, the median system of care time was 152 minutes, 
and each hour of delay from this time was associated with a decline in the likelihood of achieving a good 
outcome for the patient.28 In addition, Menon and colleagues (2016) reported that imaging to reperfusion time 
was a significant predictor of outcome in the ESCAPE trial and suggested that inefficiencies in triaging, off -
hour presentation, IV tPA administrat ion (if patient was eligible), use of general anesthesia, and endovascular 
techniques offered major opportunities for improvement in workflow.29 Finally, the guidelines for the early 
management of patients with acute ischemic stroke from the American Heart Association and American 
Stroke Association (201 8) strongly recommend streamlined stroke -specific workflows from onset of stroke 
symptoms to reperfusion of the brain, including faster triage, transport, patient evaluation, imaging, 
administration of IV tPA  (if patient is eligible), and mechanical thrombectomy techniques.[ADDRESS_908617] overall quality of life outcome for stroke patients.  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page [ADDRESS_908618] the potential to help us better understand the functional and 
quality of life outcomes fo r the millions of individuals around the world who suffer an ischemic stroke each 
year as well as to ease the global burden of this devastating disease.  
2 EXISTING CLINICAL DA TA 
The principal goal in treating acute ischemic stroke is to restore cerebral bloo d flow as rapi[INVESTIGATOR_672217]. Five clinical studies, the Thrombectomy REvascularization of large Vessel Occlusions (TREVO) in 
acute ischemic stroke, the TREVO 2 study, the MR CLEAN study, TREVO Registry, and DWI or CTP 
Assessment with Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing 
Neurointervention (DAWN™) Trial were conducted using the Trevo Retriever.   
2.[ADDRESS_908619] marketing prospective, multi -center, single arm study performed at 7 sites in 
Europe designed to quantify the performance of the Trevo Retriever in providing reperfusion and clinical 
benefit to subjects experiencing a large vessel occlusion (LVO) within 8 hours of symptom onset.31 The 
devices used in  the study were the Trevo 4 x 20 mm, Trevo Pro 4, and Trevo 3 x 10 mm.  
Sixty (60) subjects were enrolled between February [ADDRESS_908620] procedure, successful reperfusion was achieved in 91.7% of subjects. 
In the TREVO study, operators were not restricted from using intra -arterial (IA) lytic, but it was only used in 
10% of cases . 
In regard to secondary endpoints, 55.0% of subjects achieved 90 -day good clinical outcomes (mRS of 0 -2), 
the 90 -day mortality rate was 20.0%, the device -related serious adverse event rate was 5.0% and only 5.0% 
of subjects showed symptomatic  intracranial  hemorrhage (SICH) at 24 hours.   
The TREVO investigational plan pre -defined specific events that were captured to assess safety which 
included vessel dissection, vessel perforation, intracranial hemorrhage (ICH) (as identified by [CONTACT_440119]) and 
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 12 of 41 
 
 all deaths.   Information for each of these events was collected and then independently adjudicated by [CONTACT_46869] (CEC).   
2.2 TREVO 2 Study  
The TREVO 2 study was an IDE trial designed to support a 510k application for FDA clearance in the U.S.18 
The trial enrolled 178 subjects between February 3, 2011 and December 1, 2011 at 26 sites in the United 
States and one site in Spain. The subjects were randomized 1:1 to Trevo (N=88) or Merci (N=90) and were 
stratified by [CONTACT_672250] e in the two arms.  
The primary effectiveness endpoint was post -device reperfusion success defined as at least TICI 2a, which 
was achieved in 86% of patients treated with the Trevo device and 60% of patients treated with the Merci 
device. The primary safet y endpoint was a composite of adverse events. The composite rate for the Trevo 
device group was 15% and 23% for the Merci device group.  
Secondary endpoints included time to reperfusion with a mean time for the Trevo group of 47.8 44.2 minutes 
and 47.338.8 minutes. The 90 -day good outcome (mRS 0 -2) was 40% for the Trevo group and 22% for the 
Merci group, and the 90 -day mortality rate was 33% for Trevo and 24% for Merci. For the Trevo group 7% 
of patients had symptomatic ICH at 24 hours and 16% showed neuro logical deterioration at 24 hours. For the 
Merci group, 9% had symptomatic ICH at 24 hours and 22% showed neurological deterioration at 24 hours.  
Overall the results of the TREVO and TREVO 2 trials demonstrate reperfusion efficacy and safety of the 
Trevo R etriever.  
2.3 MR CLEAN Study  
MR CLEAN was a large, prospective, randomized, open label, controlled, multicenter trial in which 16 
centers in the Netherlands participated.32 Subjects with acute ischemic stroke and a proximal intracranial 
arterial occlusion of th e anterior circulation that was confirmed on vessel imaging were randomized to intra -
arterial treatment (IAT) plus usual care or usual care alone. The study enrolled 500 subjects at 16 medical 
centers.  A total of 233 subjects were randomized to IAT and 26 7 subjects to the control group of usual care.  
The primary effectiveness endpoint was to demonstrate that IAT plus usual care leads to superior functional 
independence (mRS ≤2) at 90 days compared to usual care alone. There was a shift in the distribution of the 
primary -outcome scores in favor of the intervention. The adjusted common odds ratio was 1.67 (95% CI, 1.21 
to 2.30). The shift toward better outcomes in favor of the intervention was consistent for all categories of the 
mRS, except for death.  Secon dary outcomes included: 1) NIHSS score at 24 hours and at 5 -7 days/discharge, 
2) Barthel index, and 3) EuroQol Group 5 -Dimension Self -Report Questionnaire at 90 days. The NIHSS score 
after 5 to 7 days was, on average, 2.9 points (95% CI, 1.5 to 4.3) lower in the intervention group than in the 
control group.  
This study showed that IAT in patients with acute ischemic stroke caused by a proximal intracranial occlusion 
of the anterior circulation was effective and safe when administered within 6 hours of stroke  onset.  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 13 of 41 
 
 2.4 TREVO Registry  
The Thrombectomy REVascularization  of large vessel Occlusion (TREVO) Registry is a Stryker 
Neurovascular Sponsored Registry (data on file) that is a global, multi -center, prospective, open label study. 
The only requirement of the Registry was to have a confirmed LVO and to use the Trevo Re triever as the 
initial mechanical thrombectomy device.  2008 subjects across 100 centers had been treated for ischemic 
stroke with LVO using the Trevo Retriever as the initial mechanical device for thrombectomy. Unlike prior 
randomized trials, this Registr y evaluated all clot locations, including M2 (21.0%) and vertebrobasilar 
locations (6.9%).  
Approximately 3/4 of the patients enrolled in the Registry received treatment within 6 hours of symptom 
onset; 1/4 received treatment beyond 6 hours. The mean numbe r of passes with the Trevo Retriever was 1.7, 
with 46.9% of procedures using a balloon guide catheter and 46.6% using an intermediate catheter. The first 
pass TICI 2b/3 reperfusion rate was 62% and the final TICI 2b/3 reperfusion rate was 93% post procedur e. 
The 90 -day mRS 0 -2 was 58.6% in the AHA -like cohort, and over 40% of patients showed improvement in 
NIHSS at 24 hours by 10 points or more.  
Data from the TREVO Registry are in line with the recently published HERMES meta -analysis,33 
demonstrating general izability of the Trevo Retriever in a wide range of real world endovascular cases and 
techniques.  
2.5 DWI or CTP with Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes 
Undergoing Neurointervention (DAWN™) Trial  
DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes 
Undergoing Neurointervention (DAWN™) Trial was a prospective, randomized, multi -center, open -label 
trial with a Bayesian adaptive -enrichment design. Subjects were randomized 1:1 to Trevo thrombectomy plus 
medical management or medical management alone.34  The study enrolled 206 subjects; [ADDRESS_908621] seen well.  The co -primary endpoints were the mean score for disability on the utility -weighted modified 
Rankin scale (which ranges from 0 [death] to 10 [no symptoms or disa bility]) and the rate of functional 
independence (a score of 0, 1, or 2 on the modified Rankin scale) at 90 days.  The mean score on the utility -
weighted modified Rankin scale at 90 days was 5.5 in the thrombectomy group as compared with 3.4 in the 
control  group (adjusted difference [Bayesian analysis], 2.0 points: 95% credible interval, 1.1 to 3.0; posterior 
probability of superiority, >0.999), and the rate of functional independence at 90 days was 49% in the 
thrombectomy group as compared with 13% in the control group (adjusted difference, 33 percentage points; 
95% credible interval, 24 to 44; posterior probability of superiority, >0.999).  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 14 of 41 
 
 The primary safety outcome was incidence of stroke -related mortality at 90 days.  In total, 17% (35/206) of 
the study  subjects had stroke -related mortality within 90 days of enrollment into study: 1 6% (17/107) in the 
Treatment Arm and 18% (18/99) in the Control Arm. Stroke -related mortality rates at 90 days did not differ 
significantly (p= 0.7126) between study arms.  
The study concluded that among patients with acute stroke who had last been known to be well [ADDRESS_908622] Registry .  
Refer to the approved regional Instructions for Use (IFU) for detailed instructions for use, warnings, and 
precautions.  
3.[ADDRESS_908623] of the Registry, including but not limited to:  
• AXS Infinity LS™ Long Sheath  (LS)  
• AXS Infinity LS™ Plus Long She ath 
• FlowGate2™ Balloon Guide Catheter  (BGC)  
• Merci® Balloon Guide Catheter  
• AXS Catalyst® 5 Distal Access Catheter  
• AXS Catalyst® 6 Distal Access Catheter  
• AXS Catalyst® 7 Distal Access Catheter  
• Trevo® Retriever  
• AXS Vecta™ 71 Aspi[INVESTIGATOR_672211] (Asp Cath)  
• AXS Vecta™ 74 Aspi[INVESTIGATOR_672211]  
• Medela Dominant Flex Pump  
All product sizes approved for use by [CONTACT_672251].  
3.2 Device Labeling  
A copy of the device IFU is included in each device package. Device labels and labeling generally contain 
the following information as relevant:  
• Device dimensions  
• Lot number  
• Expi[INVESTIGATOR_1516] (use before) date  
• Compatibility information  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page [ADDRESS_908624] data, including time -to-treatment an d quality of life measures, to allow for 
subset analyses that may be used for regulatory submissions and/or reimbursement dossiers.  
4.1 Primary Clinical Outcome  
1. Severity of disability at Day 90 (±14) assessed by [CONTACT_672252] a good functional outcome defined 
as mR S of 0 -2 for each technique  
4.2 Secondary Clinical Outcomes  
1. Excellent functional outcome defined as  mRS 0 -1 at Day 90 (±14)  
2. An “early response” at Discharge /Day5 -7 (whichever is earlier) defined as a NIHSS drop of ≥10 
points from baseline or NIHSS score of 0 or 1  
3. Quality of Life at Day 90 ( 14 days) assessed by [CONTACT_399128] (EQ5D5L)  
4.[ADDRESS_908625] pass  as adjudicated by [CONTACT_440119]  
4.4 Secondary Procedural Outcomes  
As adjudicated by [CONTACT_440119]:  
1. eTICI 2b50, eTICI 2b67, eTICI 2c , and/or eTICI [ADDRESS_908626] pass, after primary technique used, and 
at the end of the endovascular procedure  
2. Time from groin puncture to eTICI 2b50,  eTICI 2b67, eTICI  2c, and/or  eTICI [ADDRESS_908627] pass  
3. Overall time from groin puncture to achieve eTICI 2c or 3 and final reperfusion  
4.5 Safety Outcomes  
1. All-cause mortality and stroke -related mortality up to  Day 90 (±14)  
2. Device and /or procedure related SAEs up to  Day 90 (±14 ) 
3. Neurological deterioration at 24 ( -6/+24) hours post procedure defined as a four or more point 
increase in NIHSS from baseline  
4. Symptomatic intracranial hemorrhage (SICH) adapted from European Cooperative Acute Stroke 
Study (ECASSIII) as any apparent ext ravascular blood in the brain or within the cranium that is 
associated with clinical deterioration defined by a NIHSS increase of four points or more from 
baseline up to 24 ( -6/+24) hours  
5. Embolization to New Territory  adjudicated by [CONTACT_672253]: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page [ADDRESS_908628] data on workflow and procedural information including types of 
techniques, thr ombus location, tandem lesions, and procedure  and imaging measurements, along with time 
specific data points including:  
• Last Time Known Well (LTKW)  
• First Medical Contact  (i.e. 911, Emergency Medical Service)  
• Time of Departure from First Hospi[INVESTIGATOR_672218]  
• Time of Arrival at Treating Hospi[INVESTIGATOR_307]  
• Time of Arrival at Angio graphy  Suite  
• Time of Groin Puncture  (Time Skin Punctured by [CONTACT_672254])  
• Time of Completion  of First Pass 
• Time of Reperfusion for eTICI  2b50, eTICI 2b67, eTICI 2c, and/or eTICI  [ADDRESS_908629] Pass  
• Overall Time to eTICI 2c or 3  
• Overall Time of Final Reperfusion  
4.[ADDRESS_908630] procedure non -invasive imaging and cerebral 
angiography to include but not limited to:  
• The Alberta Stroke Program E arly CT Score (ASPECTS)  
• Collateral Flow G rade  
• eTICI Score for Each  Pass 
• Occlusion Location  
• Pre-procedure Perfusion Assessment  
• Post-procedure Hemorrhagic Transformation  
• Embolization to New Territory (ENT)  
• Vessel Size  
[ADDRESS_908631] regulatory authorization to be on the market in the geographic location of all sites.  
5.2 Duration  
The duration of the Registry protocol is approximately 48 months.  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page [ADDRESS_908632] ryker 
products utilizing one of the interventional techniques.  The objective of prior studies has focused on safety 
and effectiveness of T revo Stent Retriever, and there is limited real -world data regarding treatment techniques 
that utilize other Stryker Neurovascular devices.  
5.4 Method of Enrollment  
This Registry has open consecutive enrollment. Clinical data points will be evaluated in all su bjects who meet 
the inclusion/exclusion criteria.  
Screening and enrollment information will be maintained electronically in the Electronic Data Capture (EDC) 
by [CONTACT_672255] r subjects 
who fail to meet the study eligibility criteria.   To avoid bias, if a center chooses to participate in the ASSIST 
Registry, every effort should be made to include all thrombectomy c ases that follow one of the techniques 
that use Stryker Neurovas cular products performed over a given duration of time in the Registry.  
6 STUDY POPULATION  
6.1 Selection Criteria  
6.1.1 Inclusion Criteria  
1. Subjects  who experienced  acute ischemic stroke (AIS) ,  eligible for  restoration of blood flow using 
Stryker Neurovascular market -released products in the neurovasculature to remove thrombus  
2. Occlusion of intracranial anterior circulation vessel  
3. Subject or subject’s legally authorized representative (LAR) has signed the info rmed consent form 
prior to or within [ADDRESS_908633] 
thrombectomy pass in the neurovasculature per Instructions For Use (IFU) . 
Table 1. Thrombectomy Techniques to be Evaluated in the ASSIST  Registry  
Technique Category  Devices * 
SR Classic  SR + BGC  
SR Combination  SR + Asp Cath ± Pump + BGC or LS  
Direct Aspi[INVESTIGATOR_672212] ± Pump + BGC or LS  
*Defined d evices must be SNV market -released  products.  
 
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page [ADDRESS_908634] is participating in another device trial or any other clinical trial where the study procedure or 
treatment might confound this study’s endpoint.  
6.[ADDRESS_908635] chooses to withdraw from the Registry, the reason(s) for withdrawal 
will be recorded on the appropriate electronic Case Report Form (eCRF) and in the medical record.  
6.3 Enrollment Controls  
Enrollment  will be monitored to ensure that no more than the specified number of subjects is enrolled. The 
EDC System will be used and monitored to ensure maximum enrollment is contained.  
7 STUDY PROCEDURES  
7.1 Written Informed Consent  
An Informed Consent Form (ICF) temp late is provided in Appendix D for the Investigator to prepare for 
Institutional Review Board (IRB)/Ethics Committee (EC) submission. The ICF must be prepared in the 
language(s) of the potential subject population, document version identified, and approved by [CONTACT_266282]/EC.  A copy mu st be provided to Stryker Neurovascular. Modifications to the form must be approved by 
[CONTACT_672256].  
An ICF   must be obtained pre -procedure or up to [ADDRESS_908636]’s legally authorized representative 
(LAR) will be asked to sign the ICF. Study personnel should document the consent process in the subject’s 
medical record per Good Clinical Practice (GCP). The subje ct or LAR is to be provided a copy of the signed 
ICF. 
7.2 Pre-Procedure Assessments  
The following pre -procedure data will be obtained for subjects enrolled in the Registry : 
• Inclusion/Exclusion Criteria  
• Informed Consent  
• Demographics & Medical History  
• Baseline L abs 
• Baseli ne Pre-stroke mRS  
• Post-stroke NIHSS assessment  
• Stroke Onset  
• Neuroimaging  (CT, MR)  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 19 of 41 
 
 7.3 Procedure/Treatment  
7.3.[ADDRESS_908637] be performed to determine the appropriate procedural technique to be used for 
reperfusion. The following will be collected for subjects enrolled in the Registry:  
• The occlusion location(s)  
• A single image  when all devices are in position for each pass.  This will be the start time of the pass.  
Please note: A single image  must be performed, even if there is failure to access the clot . 
• Angiographic evaluations  with clear  visualization of the target artery  before tre atment initiation, after 
each attempt to remove thrombus from the occlusion location, and post -procedure to determine vessel 
patency. It is considered best practice to utilize the  same angiographic orientation  before and after 
device use as well as post -procedure  and to include late venous phase in the angiogram acquisition  
to allow a valid analysis of the reperfusion status of the vessel(s).  
• Expanded TICI scores  for each pass  within the vascular territory being treated .  Time of eTICI 
assessment will be th e stop time of each pass.  
Sites will submit  all de-identified angiographic  data for subjects enrolled in the Registry , rather than pre -
selecting a subset of images. If angiographic images are missing from the sequence of acquisitions, the core 
lab will req uest the site to resend the de -identified angiography dataset.  
In the event of a procedural complication or adverse event, detailed angiographic images shall be obtained 
and submitted. All adverse events and/or device malfunctions that occur during the pro cedure must be 
documented and recorded on the applicable CRFs.  
7.3.[ADDRESS_908638] current version of the 
IFU with regards to the devices’ intended use, compatibility, preparation and the recommended retrieval 
procedure.  
  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page [ADDRESS_908639] Reg istry  
Technique  Description  
SR Classic  Definition:  Referred to as the “ SR Classic” technique which combines a BGC for 
proximal flow control and retrieval with the Trevo Retriever.    
Procedural technique:  The BGC  is placed at the desired location. Using a guide 
wire, a microcatheter is then navigated through the BGC to the site of occlusion. 
Position the microcatheter tip distal to the thrombus and remove the guidewire. The 
retriever is delivered through the micro catheter and is deployed per IFU and is 
allowed to expand and integrate into the clot. Prior to retriever retraction, the BGC  
is inflated (to control antegrade flow in the ICA).   During retrieval, it is 
recommended that aspi[INVESTIGATOR_672219] C per the Trevo IFU.  
SR Combination  Definition:  Referred to as the “ SR Combination” technique which involves using 
distal aspi[INVESTIGATOR_672220] a 
stent retriever.  
• Procedural technique:  The BGC or LS is placed at the desired location.  Using a 
guide wire, the a spi[INVESTIGATOR_672221] – the aspi[INVESTIGATOR_672222].  Position the microcathete r tip distal to the thrombus and remove 
the guidewire. The retriever  is delivered through the microcatheter and is deployed 
per IFU. The retriever  is allowed to expand and integrate into the clot and 
microcatheter is removed . [For BGC Only: Prior to retriever retraction, the BGC  
is inflated (to control antegrade flow in the ICA).]  Aspi[INVESTIGATOR_672223]. Aspi[INVESTIGATOR_672224]. The retriever and aspi[INVESTIGATOR_672225].   
Direct 
Aspi[INVESTIGATOR_672226]: Referred to as the “Direct Aspi[INVESTIGATOR_51520]” technique which involves 
aspi[INVESTIGATOR_672227].  
Procedural technique: The BGC  or LS  is placed at the desired location. Using a 
guidewire, the aspi[INVESTIGATOR_1516] c atheter is navigated to the occlusion using the appropriate 
delivery catheter. Before aspi[INVESTIGATOR_1516], remove the delivery catheter and guidewire. 
Aspi[INVESTIGATOR_672228].    
 
  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 21 of 41 
 
 Table 3. Examples of Technique Products  
Technique Cat egory  Technique  Products  
SR Classic  1 SR (Trevo) + BGC ( FlowGate2 or Merci)  
SR Combination  2 SR (Trevo)  + Asp Cath (AXS Catalyst DAC, Vecta) ± Pump  + LS ( AXS 
Infinity LS, AXS Infinity LS Plus ) 
3 SR (Trevo)  + Asp Cath (AXS Catalyst DAC)  ± Pump  + BGC (FlowGate2 or 
Merci)  
Direct Aspi[INVESTIGATOR_1516]  4 Asp Cath (AXS Catalyst DAC, Vecta)  ± Pump  + LS (AXS Infinity LS, AXS 
Infinity LS Plus)  
5 Asp Cath (AXS Catalyst DAC)  ± Pump  + BGC (FlowGate2, Merci)  
Note: Additional SNV products that are comm ercialized during the conduct of the Registry may also be 
included.  
7.4 24 hours  (-6/+24) Post Procedure  
The following data will be collected at 24 hours  (-6/+24) post procedure:  
• NIHSS  
• Imaging (CT, MR)  
• Device and /or Procedure Related AEs   
• All SAEs  
• All Deaths  
Any d eath or device and/or procedure related  AEs and all SAEs should  be reported to Stryker Neurovascular 
within 24 hours of becoming aware  by [CONTACT_672257]. Available information regarding the primary cause 
of death and date/time of death will be  recorded.  
7.5 Discharge/Day 5 -7 (whichever is earlier)  
A subject may be discharged from the hospi[INVESTIGATOR_672229]’s discretion. The following data will be 
collected between Day 5 -7 (if subject  remains in the hospi[INVESTIGATOR_307]) or at discharge, whichever occurs  first:  
• mRS  
• NIHSS  
• Device and /or Procedure Related AEs   
• All SAEs  
• All Deaths  
Any death or device and/or procedure related  AEs and all SAEs should  be reported to Stryker Neurovascular 
within 24 hours of becoming aware by [CONTACT_672257]. Available information regarding the primary cause 
of death and date/time of death will be recorded.  
7.5.[ADDRESS_908640] subjects to return for follow -up assessments according to the study Time 
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page [ADDRESS_908641] completed the Day 90 (± 14) follow -up 
assessments or have discontinued the study early. Requ irements of each follow -up evaluation are detailed 
below.  
7.6 Day 30 (±14 days)  
At Day 30 (± 14 days) the following study assessments should be performed:  
• mRS (A telephone assessment may be conducted, but in -person is strongly encouraged)  
• Device and/or Procedure Related AEs 
• All SAEs  
• All Deaths  
 
Any d eath or device and/or procedure related  AEs and all SAEs should be reported to Stryker Neurovascular 
within 24 hours of becoming aware. For all subjects who expi[INVESTIGATOR_672230] 30 assessment, available 
information regarding the primary cause of death and date/time of death will be recorded.  
7.7 Day 90 (±14 days)  
At Da y 90 (± 14 days) the following study assessments should be performed:  
• mRS (A telephone assessment may be conducted, but in -person is strongly encouraged)  
• EuroQol (EQ5D5L)  
• Device and /or Procedure Related AEs   
• All SAEs  
• All Deaths  
Any d eath or device and/o r procedure related  AEs and all  SAEs should  be reported to Stryker Neurovascular 
within 24 hours of becoming aware. For all subjects who expi[INVESTIGATOR_672230] 90 assessment, available 
information regarding the primary cause of death and date/time of deat h will be recorded . 
 
  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 23 of 41 
 
 Table  4. Time and Events Schedule  
Time and Events Schedule  
Assessments:  Pre-
procedure 
(Screening 
/Baseline)  Procedure  24 (-6/+24) 
hrs. post 
procedure  Discharge 
(or Day [ADDRESS_908642])  Day 30 
±14 days  Day 90 
±14 days  
Inclusion/Exclusion 
Criteria        
Informed Consent*        
Demographics  & 
Medical History        
Baseline Labs         
mRS**        
NIHSS Assessment        
EuroQol (EQ5D5L)        
Stroke Onset       
CT/MRﻻ        
Angiogram Procedure 
Information ‡*** ﻻ        
Hospi[INVESTIGATOR_406019]/Discharge 
Disposition****        
Adverse Events‡       
Study Completion        
*Written I nformed Consent  must be obtained prior to subject enrollment and any data entry .  
**Telephone mRS assessment is acceptable if subject is not able to return in person.  
***See study binder for worksheets listing items to record during the procedure.  
****Study Staff should review the study requirements with the subject and arrange all fo llow-up visits at 
discharge.  
‡ All AE s during procedure , only D evice Related  and/or Procedure Related  AE &  all SAE, death post 
procedure.  
ﻻ CT/MR and Angiographic images will be de -identified with subject ID# if  submitted to SNV or the core 
lab. 
[ADDRESS_908643] is based on the precision of the estimate of functional independence (90 -day mRS 
0-2) in a real -world setting. The TREVO Registry had an observed rate of 55.3% with a 95% CI of [53.1, 
57.4] for functional independence and the rate is similar to that reported in a pooled analysis of [ADDRESS_908644] 
thrombectomy trials (46.0%)7. Given the uncertainty of outcomes of some of the procedural techniques a rate 
of 50% functional independence  was assumed for this study with a precision of 6%.  With a 95% Wald 
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 24 of 41 
 
 confidence interval of [47%, 53%], a sample size of 1200  observes such precision inference with a probability 
> 0.9. A 20% loss to follow -up increases the total sample size to 1200 /0.8 = [ADDRESS_908645] of the study. Assuming a minimum group size of 
72 and a total enrollment of 1500 , the maximum enrollment in any technique group is ( 1500  – 72) / 4 = 357.   
The overall sample size as well as minimum and maximum enrollment per technique provide s sufficient 
sample size to provide precise estimates of the study endpoints in each of the p rocedural techniques.  
8.[ADDRESS_908646] 95% confidence interval wi ll be 
provided. For continuous variables, total sample size, mean, standard deviation, median, minimum, and 
maximum will be provided.  
Logistic regression will be used to evaluate predictors of good outcomes in each of the techniques.  
Further details will b e provided in the SAP.  
All statistical analyses will be  performed using SAS version 9.4  or above. (Copyright © 2002 -2008 by [CONTACT_672258]., Cary, North Carolina, [LOCATION_003], all rights reserved)  
[ADDRESS_908647] protected electronic data capture (EDC) system, which is 
accessible via the Internet.  All pertinent data will be entered by [CONTACT_672259] ( eCRFs ).  A unique subject ID number will be assigned to each subject 
enrolled.   Every reasonable effort should be made to complete data entry within one week  of data collection. 
Any data discrepancies may be queried during ongoing review of data by [CONTACT_672260].   Remote monitoring may be performed to verify 
data accuracy and ensure queries are resolved. The Principal Investigator [INVESTIGATOR_672231]/he r electronic signature [CONTACT_672272].  
If images are sent to a Core Lab, the results may also be entered into the EDC system and electronically 
signed by [CONTACT_408493]. Ongoing data review will be performed to ide ntify 
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 25 of 41 
 
 possible data discrepancies. Manual and/or automatic queries will be created in the EDC system and will be 
issued to Core Lab for appropriate resolution.   
[ADDRESS_908648] igator(s) understand the 
protocol , as well as their obligations to conduct the Registry in accordance with applicable Regulations, 
GCP’s and the Registry protocol . The monitor will also confirm that the Investigator has an adequate subject 
population, faci lities, personnel and time to conduct the Registry properly.  While the Sponsor intends to use 
remote monitoring methods, periodic on-site monitoring visits will be made to confirm that the site remains 
compliant with the protocol , applicable regulations, GCP and that all agreed -upon activities are carried out 
by [CONTACT_672261].   
Data will be monitored on -site and/or remotely for completeness and logical consistency. De -identified 
procedure summary and ASSIST Registry  worksheets  sent to Stryker Neurovascular  must have the subject 
identification number recorded on any forms. The procedure documents for each subject enrolled may be 
compared against the eCRFs to ensure consistency.  
It is important that the Investigator and r elevant study site personnel are available during monitoring visits 
and that sufficient time is devoted to the process. In order to perform her or his role well, the monitor must 
be given access to primary subject medical records which support the Registry  eCRFs. This access must be 
disclosed to the subject via the informed consent.  
[ADDRESS_908649] to a quality assurance audit by [CONTACT_672262], or other regulatory 
authorities.  
12 ADVERSE EVENTS  
An Adverse Event (AE) is any untoward medical occurrence, unintended disease or injury, or untoward 
clinical sign (including abnormal laboratory findings) in subjects, users or persons, whether or not related to 
the medical device(s) . All subjects will be assessed for complications or adverse events during the procedure 
and at all follow -up visits per section 7. 4-7.7, and recorded on the AE case report form. Data to be collected 
will include the AE event term, onset and resolution dates (or whether the AE is ongoing), seriousness, 
management/treatment, outcome, and determination of the relationship to the device s and the  index 
procedure. All AEs will be followed until resolution or an appropriate endpoint is reached, or until the subject 
has completed or di scontinued the registry.  
More specifically, the following adverse events are to be reported on the Adverse Event case report form:  
• All AEs and serious adverse events (SAE) that occur during the procedure  
• Only device and/or procedure related AEs post proc edure through Day 90  
• All SAEs post procedure through Day 90   
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 26 of 41 
 
 NOTE:  Any “prolonged” hospi[INVESTIGATOR_059] (s) related to the study procedure which is considered 
standard of care due to subject age, co -morbidities or neurological status at presentation will not be 
considered SAEs  
• Any event causing neurological deterioration defined as a ≥ 4 point increase on the NIHSS from baseline 
(e.g. cerebral edema, brain herniation, stroke progression) which is related to the index stroke  
• Any event causing symptomatic intracran ial hemorrhage (SICH) defined as a ≥ 4 point increase in NIHSS 
from baseline for which the hemorrhage is determined to be the cause  
• All device -related adverse events (also known as “adverse device effects” [ADEs])  
• All serious adverse device effects (SADEs)  
• All unanticipated serious adverse device effects ([LOCATION_003]DEs)  
• All adverse events that result in death through Day 90  
NOTE:   Death should not be recorded as the AE term but should be reflected as an outcome to a 
specific AE  
Pre-treatment findings and pre -exist ing medical conditions will not be reported as AEs unless there is an 
increase in their frequency or severity during the course of the registry. Elective/planned hospi[INVESTIGATOR_672232] a SAE. Howev er, AEs that may occur during 
elective hospi[INVESTIGATOR_059], and are unrelated to the elective hospi[INVESTIGATOR_672233].  
  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 27 of 41 
 
 12.1 Adverse Event Definitions and Classification  
Term  Definition  Reference  
Adverse Event (AE)  Any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory findings) in 
a subject, users or other persons, whether or not related to the 
investigational medical device  ISO 
[ZIP_CODE]:[ADDRESS_908650] (ADE)  Any adverse event related to the use of a medical device.  
Note 1 : This definition includes adverse events resulting from 
insufficient or inadequate instructions for use, deployment, 
implantation, installation, or operation, or  any malfunction of the 
device.  
Note 2 : This definition includes any event resulting from use error 
or intentional misuse of the device  ISO 
[ZIP_CODE]:2011  
Serious Adverse 
Event (SAE)  An adverse event that:  
• led to death, or  
• resulted in a life -threatening il lness or injury, or  
• resulted in a permanent impairment of a body structure or a body 
function, or  
• required in -patient or  prolonged hospi[INVESTIGATOR_059], or  
• resulted in medical or surgical intervention to prevent life -
threatening illness or injury or permanent impairment to body 
structure or a body function, or  
• led to fetal distress, fetal death or a congenital abnormality or 
birth defect  
NOTE:  Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a 
procedure required by [CONTACT_760], without serious deterioration in 
health, is not considered a SAE  ISO 
[ZIP_CODE]:[ADDRESS_908651] 
(SADE)  An adverse device effect that has resulted in any of the 
consequences characteristic of a serious adverse event  ISO 
[ZIP_CODE]:[ADDRESS_908652] 
([LOCATION_003]DE)  Serious adverse device effect which by [CONTACT_5942], incidence, 
severity or outcome has not been identified in the current version 
of the risk analysis report   ISO 
[ZIP_CODE]:2011  
  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page [ADDRESS_908653] assess the relationship of the AE to each Stryker Neurovascular device  using the 
following criteria categories and definitions:  
• Unrelated - The AE is due to a concurrent illness or effect of another device/drug and is not related to t he 
study device.  
• Related - The AE is due to the study device (possible, probable, or highly probable).  
All AEs that are related to a Stryker device will be reported to the Stryker Neurovascular Complaint 
Management Center prompting a further investigation . Sites will be contact[CONTACT_672263].  
The Investigator must assess the relationship of the AE to the index procedure  using the following categories 
and definitions:  
• Unrelated - The AE is due to a concurrent illness or effect of a drug a nd is not related to the index 
procedure.  
• Related - The AE is due to the index procedure (possible, probable, or highly probable).  
12.3 Reporting Requirements  
Any d eath or device and/or procedure related AEs and all SAEs  should be reported within 24 hours of 
becoming aware  to Stryker Neurovascular via data entry into the eCRFs.  If access to eCRFs is not available,  
then the information can be emailed to [EMAIL_12812].  
12.[ADDRESS_908654] nonconformities will be documented 
on the appropriate eCRF, and the involved device(s) should be returned to Stryker Neurovascular for analysis 
if possible. Assistance with returning the study device(s) can b e provided by [CONTACT_672264]. Contact [CONTACT_672265]. Device 
failures and malfunctions should also be documented in the subject’s medical record.  
All Stryker Neurovascular device failures, malfunctions and product nonconformities should  be reported  
within 24 hours of becoming aware to Stryker Neurovascular via data entry into the eCRFs. If access to 
eCRFs is not available,  then the information can b e emailed to [EMAIL_12812].  
NOTE: Stryker Neurovascular device failures, malfunctions and product nonconformities should be 
reported as soon as possible after becoming aware of them and are not to be reported as adverse events. 
However, if the re is an adverse event that results from a device failure or malfunction, that specific event 
would be recorded on the appropriate eCRF.   All Stryker device failures, malfunctions, product 
nonconformities and resulting AEs are reported to the Stryker Neur ovascular Complaint Management 
Center prompting a further investigation. Sites will be contact[CONTACT_672263].  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 29 of 41 
 
 12.5 Reporting to Regulatory Authorities /  IRBs  / ECs Investigators  
Stryker Neurovascular is responsible for reporting adverse  event  information to all participating Investigators 
and regulatory authorities, as applicable.   
Any adverse event associated with the use of Stryker Neurovascular products will be reported in accordance 
with the European Medical Device Directive MDD 93/42/EEC  and MEDDEV 2.12 -1 Guidelines on a 
Medical Device Vigilance System, and local regulatory requirements.  
The Site PI [INVESTIGATOR_5703]/EC of any events  as required by [CONTACT_307970]. A copy of 
this report may be  requested by  [CONTACT_672266].  
[ADDRESS_908655] benefit from 
participation .  Possible benefits of the Registry include providing information regarding the use of the 
procedural techniques that involve Stryker Neurovascular study devices; (i.e.the AXS family of products, the 
FlowGate2 and Merci Balloon Guide Catheters , Trevo Retriever , and the Medela Dominant Flex Pump ) that 
may benefit future patients, as well as a better understanding of Quality of Life after a thrombectomy 
procedure.  
13.[ADDRESS_908656] and manuscript preparation 
and submission.   
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 30 of 41 
 
 15 ETHICAL CONSIDERATIO NS 
15.1 Compliance with Good Clinical Practices (GCP)  
The Investigator will ensure that this study is conducted in accordance with the ethical principles that have 
their origins in the Declaration of Helsinki and that are consistent with GCP and applicable regulatory (local) 
requirements; whichever affords th e greater protection to the subject.  
15.[ADDRESS_908657]  / Ethics Committee   
A copy of the protocol , proposed ICF, other written subject information, and any proposed advertising 
material (if applicable) must be submitted to the IRB/EC for written a pproval. A copy of the written IRB/EC 
initial approval of the protocol  and ICF must be received by [CONTACT_672267].  Approval from the IRB/EC  for all subsequent protocol  amendments and 
changes to the ICF must be on file with Stryker. Investigational sites must notify the IRB/EC of any events  
per local regulations.  
15.[ADDRESS_908658] be confirmed to be on file with the Stryker Neurovascular, including but not limited to: CV, 
medical license, W -8 or W -9 (where applicable), signed clinical trial agreement, IRB/EC approval of the 
study and the Informed Consent and all require d study training. A site initiation visit will be conducted prior 
to authorization to enroll. No site may begin enrolling subjects until they receive written approval from 
Stryker Neurovascular.  
16.[ADDRESS_908659] be retained for 2 years or longer per local governing  regulatory guidelines . 
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 31 of 41 
 
 16.3 Criteria for Suspending/Terminating a Study Center  
Stryker Neurovascular reserves the right to stop  or suspend a study center  at any time after site authorization 
to enroll if no subjects have been enrolled  within 6 months , or if there are concerns with data integrity.  
  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page [ADDRESS_908660] IFU: https://www.strykerneurovascular.com/us/products/access  
 
2.  CDC. Stroke Facts . Sep 2017; Available from: http://www.cdc.gov/stroke.facts.htm.  
3.  http://www.worldstrokecampaign.org/learn/facts -and-figures.html . 
4.  Goyal M, Menon BK, Zwam WH, et al.; Endovascular thrombectomy after large -vessel ischaemic  
stroke: a meta -analysis of individual patient data from five randomised trials. Lancet. 2016; p 1723 -31. 
https://doi.org/10.1016/S0140 -6736(16)[ZIP_CODE] -X. 
5.  Kennedy SA, Baerlocher MO, et al.; Meta -Analysis of Local Endovascular Therapy for Acute Ischemic 
Stroke, J Vasc Interv Radiol.;  2016 Mar; p 307 -21. 
6. Badhiwala JH, Nassiri F; Endovascular Thrombectomy for Acute Ischemic Stroke: A  Meta -analysis; 
JAMA;  2015  Nov 3; p 1832 -43. 
7.  Doerr M, et.al; Evaluation of Strategies to Reduce Time to Revascularizatio n in Acute Ischemic Stroke;  
International Stroke Conference Poster Abstract; Stroke 2017; 48:AWP411.  
8.  Darazanli C, Consoli A, Labreuche J, et al.; Impact of Modified TICI [ADDRESS_908661] Good Outcome following Endovascular Ther apy; AJNR Am J Neuroradiol. 2017 Jan; p 90 -96. 
9.  Appi[INVESTIGATOR_672234], Demchuk AM, Goyal M , et al. ; Endovascular Therapy for Ischemic Stroke; J Clin Neurol.; 
2015 Jan; p 1 -8. 
10. Goyal M, Demchuk AM, Menon BK, et al; ESCAPE Trial Investigators Randomized assessme nt of rapid 
endovascular treatment of ischemic stroke. N Engl J Med  2015; p 1019 –30 CrossRef Medline . 
11.  Turk 2014 AS, Turner R, Spi[INVESTIGATOR_204505]  A, et al.; Comparison of Endovascular Treatment Approaches for Acute 
Ischemic Stroke: Cost Effectiveness, Technical Success, and Clinical Outcomes; J Neurointerv Surg. 2015 
Sep; p 666 -70; doi 10.1136/neurintsurg -2014 -[ZIP_CODE]. Epub 2014 Jul 15; PMID: 2502850 2. 
12 . Gupta R, Vora A, Horowitz M, et al.; Multimodal Reperfusion Therapy for Acute Ischemic Stroke 
Factors Predicting Vessel Recanalization; Stroke. 2006; p 986 -990; DOI: 
10.1161/01.STR.[PHONE_13938].[ZIP_CODE].27.  
13.  Saver, J.L., et al.;  Solitaire Flow Restora tion Device Versus the Merci Retriever in P atients with Acute 
Ischaemic Stroke (SWIFT): A R andomised, Parallel -Group, Non -Inferiority Trial;  The Lancet;  2012 ; p 1241 -
1249.  
14. Nogueira, R.G., Lutsep, H.L., Gupta, R., et al., Trevo versus Merci R etrievers fo r Thrombectomy 
Revascularization of Large Vessel Occlusions in Acute Ischaemic Stroke (TREVO 2): A R andomised Trial. 
Lancet, 2012. 280: p  1231 -40. 
15.  Coutinho J , Liebeskind,D ; Slater L -A, et al.; Combined Intravenous Thrombolysis and Thrombectomy 
vs Thrombectomy Alone for Acute Ischemic Stroke: A Pooled Analysis of the SWIFT and STAR Studies; 
JAMA Neurol 2017; p 268 -274; DOI:10.1001/jamaneurol.2016.5374.  
                                                       
 
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 33 of 41 
 
                                                                                                                                                                               
 
16.  Lapergue B, Blanc R, Gory B, et al.; Effect of Endovascular Contact [CONTACT_142621][INVESTIGATOR_672235]: The ASTER 
Randomized Clinical Trial. ; JAMA . 2017 Aug 1; p 443 -452. DOI : 10.1001/jama.2017.9644 ; 
PMID:28763550  
17.  Sivan -Hoffmann R, Gory B, Rabilloud M, et al.; Patient Outcomes with Stent -Retriever Thrombectomy 
for Anterior Circulation Stroke: A Meta -Analys is and Review of the Literature; Isr Med Assoc J. 2016 Sep; 
p 561-566 
18.  Madjidvar  J, Hermes J, Freitag -Wolf S, et al.; Stent -thrombus Interaction and the Influence of Aspi[INVESTIGATOR_672236]: Evaluation of Different Stent Retrievers in a Circulation Model; 
Neuroradiology 2015 Aug; p 791 -7; DOI: 1007/s00234 -015-1526 -4; Epu b 2015 Apr 24; PMID: 25903428.  
19. Middleton S, Levi C, Dale S, et al.; Triage, Treatment and Transfer of Patients with Stroke in Emergency 
Department Trial (the T3 Trial): A Cluster Randomised Trial Protocol; Implement Sci, [ADDRESS_908662]; p 139; 
PMID 27756434.  
20. Goyal M, Jadhav AP, Bonafe A, et al.  Analysis of workflow and time to treatment and the effects on 
outcome in endovascular treatment of acute ischemic stroke;  Radiology;  2016 p. 888 -897; DOI: 
10.1148/radiol.[PHONE_13939] . 
21.  Grotta JC, Savitz SI, Persse D; Stroke Severity As Well As Time Should Determine Stroke Patient Triage; 
Stroke 2013 Feb; p 555 -7; doi: 10.1161/STROKE AHA.112669721, Epub 2013 Jan 3; PMID: 23287779.  
22.  Audebert HJ, Saver J, Starkman S, et al.; Prehospi[INVESTIGATOR_672237]: New Prospects for Treatment and 
Clinical Research; Neurology  2013 Jul 30; p 501 –508; doi:   10.1212/WNL.0b013e31829e0fdd ; PMID 
PMC3776535.  
23.  Mosley I, Nicol M, Donnan G, Patrick I, Kerr F, Dewey H. The impact of ambulance practice on acute 
stroke care. Stroke. 2007; p 2765 –2770.  
24. Meretoja A, Mustanoja S. Tatlisumak T, et al.; Reducing In -Hospi[INVESTIGATOR_672238] 20 Minutes in Stroke 
Thrombolysis; N eurology  2012  Jul; p 306 -13; DOI: 10.1212/WNL.0b013e31825d6011. Epub  2012  May 23 ; 
PMID: 22622858 . 
25. Jadhav A, Kenmuir C, Aghaebrahim A, et al.; Interfacility Transfer Directly to the Neuroangiography 
Suite in Acute Ischemic Stroke Patients Undergoing Thrombectomy; Stroke.  2017 ; 48:00 -00. DOI: 10.1161/. 
STROKEAHA.117.016946 . 
26. McTaggart RA , Yaghi S, Cutting SM, et al.; Assoc iation of a Primary Stroke Center Protocol for 
Suspected Stroke by [CONTACT_596468] -Vessel Occlusion with Efficiency of Care and Patient Outcomes; JAMA Neurol. 
2017 Jul 1; p 793 -800; doi: 10.1001/jamaneurol.2017.0477; PMID: 28492918.  
27. Schlemm L, Ebinger M, Nolte C,  Endres M; Impact of Prehospi[INVESTIGATOR_672239]; Stroke 2018; 49:00 -00; DOI: 
10.1161/STROKEAHA.117.019431.  
28.  Mueller -Kronast NH , et al.; Systematic Evaluation of Patients Treated With Neurothrombectomy Devices   
for Acute Ischemic Stroke: Primary Results of the STRATIS Registry; Stroke . [ADDRESS_908663]; p 2760 -2768; Epub 
2017 Aug 22.  
 
 
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 34 of 41 
 
                                                                                                                                                                               
 
29.  Menon B K, et al., Analysis of Workflow and Time to Treatment on Thrombectomy Outcome in the 
Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke ( ESCAPE ) Randomized, 
Controlled  Trial , Circulation . 2016 Jun 7;133, p 2279 -86, Epub 2016 Apr 13.  
30.  Powers W J, et al., June 2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early 
Management of Patients With Acute Ischemic Stroke (AIS) Regarding Endovascular Treatment,  Stroke , 
October 2015, p  3020 -3035.  
31. Wahlgren, N., Macho, J. Killer M., Liebeskind D., Jansen, O. Final Results  from the Trevo Study 
(Thrombectomy Revascularization of large Vessel Occlusions in acute ischemic stroke). International Stroke 
Conference, 2012.  
32.  Berkhemer OA, Fransen PSS, Beumer D, et al.; A randomized trial of intraarterial treatment for acute 
ischemic stroke; N Engl J Med 2015;372:11 -20; [PMID: 25517348 ]. 
33.  Goyal  M, Menon  BK, van Zwam  WH,  et al.; Endovascular  thrombectomy  after large -vessel ischaemic  
stroke:  a meta -analysis  of individual  patient  data from  five randomised  trials;  Lancet 2016; 387:1723 -31; 
[PMID:  26898852 ]. 
34. Nogueira R, Jadhav A, Haussen  D, et al.; Thrombectomy [ADDRESS_908664] (DAWN Trial); N Engl  J Med 2018;  378; p 11-21; January  4, 2018   
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 35 of 41 
 
 18 APPENDICES  
Appendix A.  Abbreviations  
Abbreviation /Acronym  Full Term  
AE Adverse Event  
AHA  American Heart Association  
AIS Acute Ischemic Stroke  
Carotid T  Distal terminus of the carotid artery  
CATO  Conventional Angiography Target Occlusion  
CRA  Clinical Research Associate  
CRF  Case Report Form  
CSA  Clinical Study Agreement  
CT Computed  Tomography  
CTA  Computed  Tomography Angiography  
DRSAE  Device -related SAE  
DSA  Digital Subtraction Angiography  
ECASIII  European Cooperative Acute Study Stroke Study III  
eCRF  electronic Case Report Form  
eTICI  (expanded) Thrombolysis in Cerebral Infarction  
EQ5D5L  EuroQol Questionnaire – 5 Level 5D Version  
GCP  Good Clinical Practices  
IA Intra -Arterial  
IAT Intra -Arterial Therapy  
ICH Intracranial Hemorrhage  
ID Identification  
IFU Instructions For Use  
IV Intravenous  
IV tPA  Intravenous tissue Plasminogen Activator  
LAR  Legally Authorized Representative  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
 
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                    
  Page 36 of 41 
 
 Abbreviation /Acronym  Full Term  
LTKW  Last Time Known Well  
LVO  Large Vessel Occlusion  
MR Magnetic Resonance  
MRI  Magnetic Resonance Imaging  
mRS  Modified Rankin Scale  
PI [INVESTIGATOR_672240]  
t-PA Tissue Plasminogen Activator  
UADE  Unanticipated Adverse Device Effect  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                                
Page 37 of 41 
 Appendix B.  Definitions  
Access Site Complication:  Complication related to the vascular access site for the index procedure including 
but not limited to bleeding, hematoma, pseudoaneurysm, tears, pain or occlusion  requiring  additional treatment 
such as blood transfusion or surgical repair.  
Adverse Event (AE):  Any untoward medical occurrence, unintended disease or injury or untoward clinical 
sign (including abnormal laboratory results) in subjects, users, or other persons.  NOTE - This d efinition does 
not imply that there is a relationship between the adverse event and the device under investigation.  
At Risk Tissue -Volume:  Differentiate tissue at risk, but salvageable, from tissue that is already infarcted and 
at risk for hemorrhage with reperfusion  
Device Malfunction/Nonconformity:  The failure of a device to meet its performance specifications or 
otherwise perform as intended. Performance specifications include all claims made in the labeling for the 
device. The intended performance of a device refers to the intended use for which the device is labeled or 
marketed.  
Distal Embolization (DE):  Any downstream occlusion distal to the conventional angiography target occlusion 
(CATO) , into the target ischemic territory, is considered DE unless c omplete angiogram or pre procedure non -
invasive imaging demonstrated non-patency of these distal branches.  
Early Response:  A NIHSS drop of ≥10 from baseline or an excellent score of NIHSS 0 or 1  at Discharge/ Day 
5-7 (whichever is earlier).  
Embolization to New Territory (ENT):  Embolization into a previously uninvolved area of the brain  associated 
with new ischemic changes on [ADDRESS_908665] 
procedure is considered distal embolization (DE) and not ENT. However, if pre procedure patency of these 
previously uninvolved territories is documented by [CONTACT_672268] -intervention non -invasive 
imaging, then it would be considered ENT.  
Epi[INVESTIGATOR_307865]:  Blood between the dura mater and the arachnoid mater.  
Good Clinical Outcome:  A measure of neurologic functional outcome with a score of 0 –2 on the modified 
Rankin Scale (mRS), usually assessed 90 days after treatment.  
Groin Puncture:  Time Skin Punctured by [CONTACT_672254].  
Intracranial hemorrhage:  A hemorrhage, or bleeding, within the skul l 
Intramural arterial dissection:   A tear or damage to the inner arterial wall that occurs during the index 
procedure.  The intramural arterial dissection may be identified angiographically as minor radiolucent area to 
luminal filling defect on imaging.   
Intraprocedure Mortality:   Death occurring during the index thrombectomy procedure  
Intra -ventricular Hemorrhage (IVH):  Bleeding into the brain's ventricular system.  
In vivo  (breakage) device failure:   Breakage of the Trevo device in the vasculature during  the index procedure.  
Modified Rankin Scale:  Scale for measuring the degree of disability or dependence in the daily activities of 
people who have suffered a stroke or other causes of neurological disability.  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                                
Page 38 of 41 
 Neurological worsening:   A 4 or more point incr ease in NIHSS from baseline.  Neurological worsening could 
be new or evolution/progression of the index stroke.  
NIHSS Score:  An assessment to objectively quantify the impairment caused by a stroke. It is composed of 11 
items, each of which scores a specifi c ability. For each item, a score of 0 typi[INVESTIGATOR_672241], while a higher score is indicative of some level of impairment. The individual scores from 
each item are summed in order to calculate a total NIHSS score. The maximum possible score is 42, with the 
minimum score being a 0.  
Parenchymal hemorrhage type 1 (PH -1):  A hematoma in < 30% of the infarcted area with some slight space -
occupying effect.  
Parenchymal hemorrhage type 2 (PH -2):  Dense hematoma > 30% total  of the infarcted area with substantial 
space -occupying effect or any hemorrhage area outside the infarcted area.  
Pass (Start Time and Stop Time):  
Start Time  is the time of the single image  performed when all devices are in position for each pass.  
Stop Time  is the time of the eTICI assessment completed after the pass.  
Petechial hemorrhage type I (HI -1): Small petechiae along the margins of the infarct.  
Petechial hemorrhage type II (HI -2): More confluent petechiae within the infarcted area but without spa ce-
occupying effect  
Pre-stroke disability:  Obtained at baseline, but representative of the subject’s status before the index stroke, 
assessed by [CONTACT_672269]’s medical chart, or family members.  
Remote Intracerebral Hemorrhag e (RIH):  Any intraparenchymal hemorrhage remote from the ischemic 
field.  
Serious Adverse Device Effect (SADE):   Any serious adverse effect on health or safety or any life -threatening 
problem or death caused by, or associated with, a device, if that effect,  problem, or death was not previously 
identified in nature, severity, or degree of incidence in the protocol  or application (including a supplementary 
plan or application), or any other unanticipated serious problem associated with a device that relates to  the 
rights, safety or welfare of subjects.   
Serious Adverse Event (SAE):  An adverse event in a research subject that led to a death, or led to a serious 
deterioration in the health of the subject that resulted in a life -threatening illness or injury, or resulted in a 
permanent impairment of a body structure or a body function, or required in -patient hospi[INVESTIGATOR_8448], or resulted in medical or surgical intervention to prevent permanent 
impairment to body structure  or a body function. SAEs are a subset of AEs.  
• NOTE 1 – This definition does not imply that there is a relationship between the serious adverse 
event and the device under investigation.  
• NOTE 2 – Elective/planned hospi[INVESTIGATOR_672242] a SAE.  However, AEs that may occur during elective hospi[INVESTIGATOR_059], and are unrelated to the 
elective hospi[INVESTIGATOR_672243].  
 
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                                
Page 39 of 41 
  
Stroke:   An acute neurological event with focal sympto ms and signs lasting ≥ 24 hours.  Stroke can be sub -
classified as Hemorrhagic or Ischemic.  
• Hemorrhagic Stroke:   A symptomatic intracerebral, subarachnoid, or primary intraventricular 
hemorrhage.  To be considered a hemorrhagic stroke, the patient must experience new symptoms 
(e.g., new severe headache) that last for at least 24 hours (symptoms do not need to be as sociated 
with a new neurological deficit).  
• Ischemic Stroke:   A neurological deficit that is thought to have an ischemic cause and is detectable 
on examination at least 24 hours after onset of symptoms.       
Stroke -related Death:  Death related to the index  stroke; to systemic complications associated with the index 
stroke, or a new stroke.  
Subarachnoid Hemorrhage (SAH):  Bleeding into the subarachnoid space - the area between the arachnoid 
membrane and the pia mater surrounding the brain.  
Subdural hemorrhag e: Blood between the dura mater and the skull.  
Symptomatic ICH (SICH):  The primary protocol definition is adapted from ECASS III as any apparently 
extravascular blood in the brain or within the cranium that is associated with clinical deterioration as defi ned 
by [CONTACT_672270], or that led to death and was judged to be the predominant 
cause of a neurologic deterioration.  The SITS -MOST definition of SICH is: Any PH -2 with a four point or 
more increase in NIHSS.  
Unanticipated  Serious Adverse Device Effects ([LOCATION_003]DEs):  Any serious adverse effect on health or safety, 
any life -threatening problem or death caused by, or associated with a device, if that effect, problem, or death 
was not previously identified in nature, severity, or degree of incidence in the application; or any other 
unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.  
Vessel Perforation:   A hole or puncture (perforation) in the vessel wall that occurs uni ntentionally during the 
index procedure.  The perforations may be seen angiographically during  the index procedure by [CONTACT_672271].  
 
  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                                
Page 40 of 41 
 Appendix C.  Expan ded TICI (eTICI) Perfusion Categories  
• Grade  0: Equivalent to no reperfusion or 0% filling of the downstream territory . 
• Grade 1: Reflects thrombus reduction without any reperfusion of distal arteries . 
• Grade  2a: Reperfusion in less than half or 1 –49% of the territory . 
• Grade 2 b50: 50–66% reperfusio n 
• Grade 2b67 : 67-89% reperfusio n 
• Grade 2 c: 90–99% reperfusion  
• Grade  3: Complete or 100% reperfusion  
 
Reference  
Liebeskind DS, Bracard S, Guillemin F, et al eTICI  reperfusion: defining success in endovascular stroke therapy Journal 
of NeuroInterventional Surgery Published Online First: 07 September 2018. doi: 10.1136/neurintsurg -2018 -014127  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Stryker Neurovascular  
Document Title: ASSIST™ Registry Protocol  
Document Number:  CDM10001414  Rev:  AB  
STRYKER CONFIDENTIAL  - THIS DOCUMENT CONTAINS CONFIDENTIAL AND PROPRIETARY INFORMATION THAT IS THE 
PROPERTY OF STRYKER CORPORATION. NEITHER THIS DOCUMENT NOR THE INFORMATION HEREIN MAY BE REPRODUCED, 
USED, OR DISCLOSED TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF S TRYKER CORPORATION.                                                                                                                                                                                
Page 41 of 41 
 Appendix D.  Informed Consent Form Template  
 